Leukemia, Myeloid: all 2,432 studies
Page 10 of 25. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.
- Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive InductionWithdrawnNCT05766514Phase 2
- Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent LineCompletedNCT05734053
- Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT05722171Early Phase 1
- Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid LeukemiaWithdrawnNCT05720988Phase 1
- A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeStatus unknownNCT05703204Phase 1
- Effects of Music Therapy in Controlling Symptoms in Patients With AML and Undergoing HSCTCompletedNCT05696457Not applicable
- Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)TerminatedNCT05682170Phase 1/2
- Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT05659992Phase 2
- A Bioequivalence Study of Dasatinib TabletCompletedNCT05640804Phase 1
- Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous LeukemiaStatus unknownNCT05638763Phase 2
- US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid LeukemiaNo longer availableNCT05627466
- ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AMLWithdrawnNCT05622591Phase 1
- French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML PatientsCompletedNCT05619978
- Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I MutationCompletedNCT05611216
- The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCTStatus unknownNCT05596981
- The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCTStatus unknownNCT05596968
- Mobile Intervention to Improve Adherence of Oral Anti-cancer Medications Among Acute Myeloid Leukemia Patients, the txt4AML StudyWithdrawnNCT05595135Not applicable
- Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)Status unknownNCT05587088Phase 1/2
- An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)Status unknownNCT05577611Phase 1
- Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid LeukemiaStatus unknownNCT05574608Early Phase 1
- Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AMLTerminatedNCT05569512Phase 1
- Application of Health Education Path of Traditional Chinese Medicine NursinCompletedNCT05563207Not applicable
- LILRB4 STAR-T Cells in the Treatment of R/R AML/CMMLCompletedNCT05548088Phase 1
- "Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker"Status unknownNCT05543161
- A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic MarkersCompletedNCT05541224
- STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL AmyloidosisWithdrawnNCT05519527Phase 1
- LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT05518357Phase 1
- Clinical Characters and Outcome of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56 ExpressionStatus unknownNCT05512104
- Psychological Mobile App for Patients With AMLTerminatedNCT05501171Not applicable
- Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)CompletedNCT05488613
- Study Conducted Among Patients With CMLCompletedNCT05476562
- Phase I Clinical Trial of RC1012 Injection in Patients With r/r AMLStatus unknownNCT05471323Phase 1
- Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid LeukemiaCompletedNCT05458258
- A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDSWithdrawnNCT05456269Phase 1
- Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AMLCompletedNCT05456048
- G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCTStatus unknownNCT05449899Phase 2/3
- A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDSStatus unknownNCT05448599Phase 1/2
- Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid LeukemiaStatus unknownNCT05445765Phase 1
- TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) PatientsActive, not recruitingNCT05434312Phase 1
- Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP PatientsCompletedNCT05433532Phase 2
- Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic SyndromesStatus unknownNCT05426798Phase 1
- Special Drug Use-results Surveillance of Scemblix TabletsCompletedNCT05421091
- Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AMLStatus unknownNCT05404516Phase 2
- Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib TreatmentCompletedNCT05387330
- FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia.Status unknownNCT05383014
- Decitabine and HQP1351-based Chemotherapy Regimen for the Treatment Advanced CMLStatus unknownNCT05376852Phase 2
- A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS ParticipantsWithdrawnNCT05367401Phase 1/2
- Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in ScotlandCompletedNCT05363488
- Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid LeukemiaStatus unknownNCT05362942Phase 2
- Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid LeukemiaActive, not recruitingNCT05356169Phase 2/3
- A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid LeukemiaTerminatedNCT05345938Phase 1/2
- Donor Immune Cell Therapy for Acute Myeloid LeukemiaStatus unknownNCT05333705Phase 1
- GM-CLAG in Relapsed/Refractory FLT3-mutated AMLWithdrawnNCT05330377Phase 1
- Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid LeukemiaStatus unknownNCT05330364Phase 2
- Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory LeukemiasWithdrawnNCT05321940Phase 1
- A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to TreatWithdrawnNCT05320380Phase 1/2
- Real World Outcomes Using Novel Agents for AML in the UKStatus unknownNCT05312112
- Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AMLWithdrawnNCT05309018
- Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid AcidStatus unknownNCT05297123Phase 1
- Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT05266950Phase 1
- Clinical Efficacy and Safety of CD47 Monoclonal Antibody Combined With Azacitidine in the Treatment of Recurrent AML After TransplantationStatus unknownNCT05266274Not applicable
- MargheRITA (Remote Intelligence for Therapeutic Adherence)CompletedNCT05260203Not applicable
- Evaluation of Infective Risk, Efficacy of Bacterial Prophylaxis and Validation of Sepsis Scores NEWS (National Early Warning Score) and qSOFA (Quick Sequential Organ Failure Assessment) in Patient With Acute Myeloid Leukemia Treated With Intensive ChemotherapyStatus unknownNCT05249894
- Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid LeukemiaWithdrawnNCT05248685Phase 1
- NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT05247957Not applicable
- Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)TerminatedNCT05223699Phase 1
- Managed Access Programs for PKC412, MidostaurinNo longer availableNCT05219266
- A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)CompletedNCT05218902
- Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid LeukemiaStatus unknownNCT05215015Early Phase 1
- Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly PatientsCompletedNCT05188326Phase 3
- CPX-351 Real-World Effectiveness and Safety StudyCompletedNCT05169307
- Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic MalignancyStatus unknownNCT05154474
- Vitamin D Effect on A Disintegrin-like And Metalloprotease Thrombospondin1 Motif 13& Interleukin 6 in LeukemiaCompletedNCT05149339Phase 1/2
- Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic PhaseActive, not recruitingNCT05143840Phase 2
- RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.Status unknownNCT05127798
- Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction TherapiesStatus unknownNCT05123352
- PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesTerminatedNCT05107856Phase 1
- A Study for PRO of CML in Real WordStatus unknownNCT05092048
- Myeloid Mutations Register in R/R CMLStatus unknownNCT05080829Not applicable
- Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCTStatus unknownNCT05066958Phase 1/2
- A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)Status unknownNCT05061147Phase 1/2
- Extramedullary Acute Myeloid Leukemia (eAML): Retrospective Single Center Cohort Study, Clinicopathological, Molecular Analysis and Survival OutcomesCompletedNCT05057299
- Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AMLStatus unknownNCT05053425Not applicable
- Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid LeukemiaStatus unknownNCT05042531Not applicable
- Anti-Leukemia Immune Responses After Irradiation of Extramedullary TumorsActive, not recruitingNCT05035706Early Phase 1
- Application of Nanopore Sequencing in Newly Diagnosed Acute Myeloid Leukemia Patients With Bloodstream InfectionStatus unknownNCT05016752
- Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT05016063Early Phase 1
- Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT05008575Phase 1
- Study of GDX012 in Patients With MRD Positive AMLTerminatedNCT05001451Phase 1
- Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative NeoplasmCompletedNCT04992949Phase 2
- A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid LeukemiaActive, not recruitingNCT04980885Phase 1/2
- Oral Health Condition and Quality of Life in Children With LeukemiaTerminatedNCT04968860
- Is There an Association Between Innate CD8+ T Cells and the Evolution of Tyrosine Kinase Inhibitor Resistance Mutations in Phi+ Hematological Malignancies.CompletedNCT04965649
- Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT04956042Phase 1/2
- A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT04946890Phase 1/2
- Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid MalignanciesCompletedNCT04943757Phase 2
- The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP PatientsStatus unknownNCT04933526Phase 4
- A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)CompletedNCT04925141Phase 4
- Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML)TerminatedNCT04920188
- Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic SyndromeTerminatedNCT04912063Phase 1